Neurocrine Biosciences Inc vs Norfolk Southern Corporation — how do they compare? Neurocrine Biosciences Inc trades at $179.88 (market cap $17.40B), while Norfolk Southern Corporation trades at $333.48 (market cap $75.23B). The key difference: Norfolk Southern Corporation is far larger — about 4.3× Neurocrine Biosciences Inc's market cap, and Norfolk Southern Corporation pays a 1.61% dividend while Neurocrine Biosciences Inc pays none. Which is the better fit depends on your goals.
| NBIX | NSC | |
|---|---|---|
Market Cap | $17.40B | $75.23B |
Sector | Health | Technology |
52-Week High | $180.55 | $340.16 |
52-Week Low | $123.10 | $272.35 |
Enterprise Value | $16.49B | $90.99B |
Dividend Yield | — | 1.61% |
Trailing returns across standard periods
Latest headlines on both assets
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →Norfolk Southern Corporation is a major North American railroad company operating one of the largest freight rail networks in the eastern United States. The company transports a diverse range of commodities, including coal, intermodal containers, and various industrial products. NSC is a critical link in the nation's supply chain, providing efficient, long-haul transportation services to and from ports and industrial centers.
Read more on NSC →